Latest & greatest articles for Polypharmacy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Polypharmacy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Polypharmacy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Polypharmacy

1. Use of an electronic decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster randomised controlled trial. Full Text available with Trip Pro

Use of an electronic decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster randomised controlled trial. To evaluate the effects of a computerised decision support tool for comprehensive drug review in elderly people with polypharmacy.Pragmatic, multicentre, cluster randomised controlled trial.359 general practices in Austria, Germany, Italy, and the United Kingdom.3904 adults aged 75 years and older using eight or more drugs on a regular basis, recruited (...) -0.63 to -0.26; P<0.001).In intention-to-treat analysis, a computerised decision support tool for comprehensive drug review of elderly people with polypharmacy showed no conclusive effects on the composite of unplanned hospital admission or death by 24 months. Nonetheless, a reduction in drugs was achieved without detriment to patient outcomes.Current Controlled Trials ISRCTN10137559.© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights

2020 BMJ

2. Effect of Clinical Geriatric Assessments and Collaborative Medication Reviews by Geriatrician and Family Physician for Improving Health-Related Quality of Life in Home-Dwelling Older Patients Receiving Polypharmacy: A Cluster Randomized Clinical Trial (Abstract)

Effect of Clinical Geriatric Assessments and Collaborative Medication Reviews by Geriatrician and Family Physician for Improving Health-Related Quality of Life in Home-Dwelling Older Patients Receiving Polypharmacy: A Cluster Randomized Clinical Trial Polypharmacy and inappropriate drug regimens are major health concerns among older adults. Various interventions focused on medication optimization strategies have been carried out, but the effect on patient-relevant outcomes remains uncertain.To (...) , reduced dosages, and new drug regimens started in the intervention group.This study's findings indicate that, among older patients exposed to polypharmacy, clinical geriatric assessments and collaborative medication reviews carried out by a geriatrician in cooperation with the patient's FP can result in positive effects on health-related quality of life.ClinicalTrials.gov identifier: NCT02379455.

2019 EvidenceUpdates

3. Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: A randomised controlled trial (DREAMeR-study) Full Text available with Trip Pro

Effects of a clinical medication review focused on personal goals, quality of life, and health problems in older persons with polypharmacy: A randomised controlled trial (DREAMeR-study) Clinical medication reviews (CMRs) are increasingly performed in older persons with multimorbidity and polypharmacy to reduce drug-related problems (DRPs). However, there is limited evidence that a CMR can improve clinical outcomes. Little attention has been paid to patients' preferences and needs. The aim (...) of this study was to investigate the effect of a patient-centred CMR, focused on personal goals, on health-related quality of life (HR-QoL), and on number of health problems.This study was a randomised controlled trial (RCT) performed in 35 community pharmacies and cooperating general practices in the Netherlands. Community-dwelling older persons (≥70 years) with polypharmacy (≥7 long-term medications) were randomly assigned to usual care or to receive a CMR. Randomisation was performed at the patient level

2019 EvidenceUpdates

4. How Can You Best Address Polypharmacy in the Elderly?

How Can You Best Address Polypharmacy in the Elderly? How Can You Best Address Polypharmacy in the Elderly? – Clinical Correlations Search How Can You Best Address Polypharmacy in the Elderly? December 21, 2017 5 min read By Michael Nguyen Peer Reviewed Polypharmacy has been defined as the use of multiple unnecessary medications, the use of more medications than is clinically warranted or indicated, .[1–3] Problematic polypharmacy should be differentiated from appropriate polypharmacy (...) , with increased .[8] In the geriatric population, polypharmacy is associated with increased falls and hip fracture frequency,[10] incontinence,[11] malnutrition, and drug-drug interactions. In addition to medical complications, the pill burden of polypharmacy causes poorer adherence to prescribed medications, which can already be particularly difficult in the geriatric population, in whom cognitive impairment and memory loss are more common. Many of these adverse drug events are preventable. In the ambulatory

2018 Clinical Correlations

5. Prevalence and Variability in Medications Contributing to Polypharmacy in Long-Term Care Facilities Full Text available with Trip Pro

Prevalence and Variability in Medications Contributing to Polypharmacy in Long-Term Care Facilities Research into which medications contribute to polypharmacy and the variability in these medications across long-term care facilities (LTCFs) has been minimal.Our objective was to investigate which medications were more prevalent among residents with polypharmacy and to determine the variability in prescribing of these medications across LTCFs.This was a cross-sectional study of 27 LTCFs (...) in regional and rural Victoria, Australia. An audit of the medication charts and medical records of 754 residents was performed in May 2015. Polypharmacy was defined as nine or more regular medications. Logistic regression was performed to determine the association between medications and resident characteristics with polypharmacy. Analyses were adjusted for age, sex and Charlson's comorbidity index. Variability in the use of the ten most prevalent medication classes was explored using funnel plots

2017 Drugs - real world outcomes

6. Multimorbidity and polypharmacy

Multimorbidity and polypharmacy Multimorbidity and polypharmacy Multimorbidity and polypharmacy Key therapeutic topic Published: 16 January 2017 nice.org.uk/guidance/ktt18 pathways K Ke ey points y points Multimorbidity is associated with reduced quality of life, higher mortality, polypharmacy and high treatment burden, higher rates of adverse drug events, and much greater health services use (including unplanned or emergency care). Polypharmacy in people with multimorbidity is often driven (...) implementation: Develop and agree an action plan for multimorbidity and polypharmacy to inform local medicines optimisation strategic and operational plans. Shared learning case studies are available showing how NICE guidance and standards have been put into practice by a range of NHS organisations. Encourage and support a shared decision-making approach to care: see the related NICE key therapeutic topic on shared decision making that discusses this in more detail. Develop an individualised, person-centred

2017 National Institute for Health and Clinical Excellence - Advice

7. Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis Full Text available with Trip Pro

Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis A lack of gold standard treatment for autism spectrum disorders (ASD), no clear ASD management guidelines, and lack of evidence-based pharmacological interventions other than aripiprazole and risperidone elevate the risk of off-label prescribing and adverse effects among individuals with ASD, more so among adults.The aim of this study was to identify and compare the types (...) of prescription drug use, rates of polypharmacy, and characteristics associated with polypharmacy among adults with and without ASD in a retrospective cross-sectional analysis of a three-state Medicaid Analytic eXtract database (2000-2008).Adults aged 22-64 years with ASD (ICD9-CM code: 299.xx) were propensity score-matched to 'no ASD' controls by age, sex, and race. General polypharmacy (≥6 unique classes of prescription drugs in a year) and psychotropic polypharmacy (≥3 unique prescription drug classes

2016 Drugs - real world outcomes

8. Prevalence of Central Nervous System Polypharmacy and Associations with Overdose and Suicide-Related Behaviors in Iraq and Afghanistan War Veterans in VA Care 2010–2011 Full Text available with Trip Pro

Prevalence of Central Nervous System Polypharmacy and Associations with Overdose and Suicide-Related Behaviors in Iraq and Afghanistan War Veterans in VA Care 2010–2011 The increase in the quantities of central nervous system (CNS)-acting medications prescribed has coincided with increases in overdose mortality, suicide-related behaviors, and unintentional deaths in military personnel deployed in support of the wars in Iraq and Afghanistan. Data on the extent and impact of prescribing (...) multiple CNS drugs among Iraq and Afghanistan Veterans (IAVs) are sparse.We sought to identify the characteristics of IAVs with CNS polypharmacy and examine the association of CNS polypharmacy with drug overdose and suicide-related behaviors controlling for known risk factors.This cross-sectional cohort study examined national data of Iraq and Afghanistan Veterans (N = 311,400) who used the Veterans Health Administration (VHA) during the fiscal year 2011. CNS polypharmacy was defined as five or more

2016 Drugs - real world outcomes

9. Comorbidity-Polypharmacy Score as Predictor of Outcomes in Older Trauma Patients: A Retrospective Validation Study (Abstract)

Comorbidity-Polypharmacy Score as Predictor of Outcomes in Older Trauma Patients: A Retrospective Validation Study Traditional injury severity assessment is insufficient in estimating the morbidity and mortality risk for older (≥45 years) trauma patients. Commonly used tools involve complex calculations or tables, do not consider all comorbidities, and often rely on data that are not available early in the trauma patient's hospitalization. The comorbidity-polypharmacy score (CPS), a sum of all

2015 EvidenceUpdates

10. Polypharmacy and medicines optimisation

Polypharmacy and medicines optimisation Polypharmacy and medicines optimisation | The King's Fund Main navigation Health and care services Leadership, systems and organisations Patients, people and society Policy, finance and performance Search term Apply Polypharmacy and medicines optimisation: Making it safe and sound This content relates to the following topics: Share this content Related details Authors Martin Duerden Tony Avery Rupert Payne Publication details ISBN 978 1 909029 18 7 Pages (...) 68 Polypharmacy – the concurrent use of multiple medications by one individual – is an increasingly common phenomenon that demands attention at clinical policy and practice level. Driven by the growth of an ageing population and the rising prevalence of multi-morbidity, polypharmacy has previously been considered something to avoid. It is now recognised as having both positive and negative potential, depending on how medicines and care are managed. This report proposes a pragmatic approach

2013 The King's Fund

11. Comorbidity-Polypharmacy Scoring Facilitates Outcome Prediction in Older Trauma Patients (Abstract)

Comorbidity-Polypharmacy Scoring Facilitates Outcome Prediction in Older Trauma Patients To determine the association between comorbidity-polypharmacy score (CPS) and clinical outcomes in a large sample of older trauma patients, focusing on outcome prognostication.The CPS combines number of preinjury medications and comorbidities to more objectively quantify the severity of comorbid conditions.An urban tertiary care level 1 trauma center in the Midwest.Trauma patients aged 45

2012 EvidenceUpdates

12. Regional variation in antipsychotic polypharmacy for schizophrenia Full Text available with Trip Pro

Regional variation in antipsychotic polypharmacy for schizophrenia Regional variation in antipsychotic polypharmacy for schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Regional variation in antipsychotic polypharmacy for schizophrenia Article Text Prevalence Regional variation in antipsychotic polypharmacy for schizophrenia Statistics from Altmetric.com Question Question Are there regional differences in the attitudes

2011 Evidence-Based Mental Health

13. [Antipsychotic polypharmacy in the treatment of schizophrenia]

[Antipsychotic polypharmacy in the treatment of schizophrenia] Antipsykotisk polyfarmaci i behandlingen af skizofreni [Antipsychotic polypharmacy in the treatment of schizophrenia] Antipsykotisk polyfarmaci i behandlingen af skizofreni [Antipsychotic polypharmacy in the treatment of schizophrenia] Baandrup L, Lublin H, Nordentoft M, Peacock L, Sorensen J, Andersen SE, Glenthoj B Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Baandrup L, Lublin H, Nordentoft M, Peacock L, Sorensen J, Andersen SE, Glenthoj B. Antipsykotisk polyfarmaci i behandlingen af skizofreni. [Antipsychotic polypharmacy in the treatment of schizophrenia] Copenhagen: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). Volume 11(1). 2011 Authors' objectives The aim of this health technology assessment is to explore how antipsychotic polypharmacy

2011 Health Technology Assessment (HTA) Database.

14. Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy

Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy Antipsychotic polypharmacy is not associated with increased mortality from natural causes in patients with schizophrenia compared to monotherapy | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how (...) we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Antipsychotic polypharmacy is not associated with increased mortality from natural causes

2010 Evidence-Based Mental Health

15. Periodic telephone counselling for polypharmacy improved compliance and reduced mortality

Periodic telephone counselling for polypharmacy improved compliance and reduced mortality Periodic telephone counselling for polypharmacy improved compliance and reduced mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Periodic telephone counselling for polypharmacy improved compliance and reduced mortality Article Text Therapeutics Periodic telephone counselling for polypharmacy improved compliance and reduced mortality Statistics

2008 Evidence-Based Medicine

16. Treatment review by case conferences led to more medication changes than written feedback in older people on polypharmacy

Treatment review by case conferences led to more medication changes than written feedback in older people on polypharmacy Treatment review by case conferences led to more medication changes than written feedback in older people on polypharmacy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Treatment review by case conferences led to more medication changes than written feedback in older people on polypharmacy Article Text

2008 Evidence-Based Medicine

17. Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model

Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model Newman J, Grobman W A, Greenland P Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) . This polypharmacy approach was cost-effective in comparison with no treatment. The study was generally well conducted and was based on valid methodology although some aspects of the analysis were not extensively reported. Overall, the authors’ conclusions appear to be valid. Type of economic evaluation Cost-utility analysis Study objective The objective was to examine the cost-effectiveness of a combination of four fixed-dose medications in comparison with no treatment for the prevention of primary

2008 NHS Economic Evaluation Database.

18. Polypharmacy in elderly patients

Polypharmacy in elderly patients Polypharmacy in elderly patients Polypharmacy in elderly patients Hajjar ER, Cafiero AC, Hanlon JT CRD summary This review concluded that various numbers of medications were associated with negative health outcomes, but more research was required to determine the consequences associated with unnecessary drug use. The conclusions did not address the apparent efficacy of interventions to reduce polypharmacy. Due to limitations in the methodology and reporting (...) of the review, the reliability of these results is unclear. Authors' objectives To review attempts to reduce polypharmacy in older adults and to assess adverse events associated with polypharmacy. The review also examined the epidemiology of polypharmacy (outside the scope of this abstract). Searching MEDLINE and International Pharmaceutical Abstracts were searched from 1986 to June 2007. Search terms were reported. References of identified studies and authors' files, book chapters and recent reviews were

2007 DARE.

19. Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia Full Text available with Trip Pro

Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia Article Text Prevalence Long term antipsychotic polypharmacy is common among Medicaid recipients with schizophrenia Free

2006 Evidence-Based Mental Health

20. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. Full Text available with Trip Pro

Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. To investigate the effects of compliance and periodic telephone counselling by a pharmacist on mortality in patients receiving polypharmacy.Two year randomised controlled trial.Hospital medical clinic.502 of 1011 patients receiving five or more drugs for chronic disease found to be non-compliant at the screening visit were invited for randomisation (...) with compliance scores of 34-66% and 0-33%, respectively, compared with those who had a compliance score of 67% or more.In patients receiving polypharmacy, poor compliance was associated with increased mortality. Periodic telephone counselling by a pharmacist improved compliance and reduced mortality.International Standard Randomised Controlled Trial Number Register: SRCTN48076318.

2006 BMJ Controlled trial quality: predicted high